GlassScriptPhysician profile
Ryan Chase Sperl
NPI 1912410408
$17,510.73
in general payments reported to CMS, 2019-2025
70 companies · $4,228 in 2025
The $4,228 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,675 · 2022: $3,498 · 2023: $3,900 · 2024: $3,211 · 2025: $4,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,337.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,917.76 | 2021-2025 | Imfinzi, Calquence, Lynparza |
| Janssen Biotech, INC. | $1,188.42 | 2022-2025 | Erleada, Rybrevant, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $1,005.67 | 2021-2025 | Opdivo, Reblozyl, Opdualag |
| Myriad Genetic Laboratories, INC. | $983.62 | 2021-2025 | Myrisk, Precisetumor |
| Merck Sharp & Dohme LLC | $767.07 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Gilead Sciences, INC. | $630.35 | 2021-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $541.31 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Genzyme Corporation | $514.50 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $447.78 | 2021-2025 | Libtayo, Lynozyfic |
| Genentech USA, INC. | $433.81 | 2021-2025 | Tecentriq, Polivy, Lunsumio |
| Takeda Pharmaceuticals U.S.A., INC. | $394.06 | 2021-2025 | Ninlaro, Vpriv, Fruzaqla |
| Lilly USA, LLC | $384.02 | 2021-2025 | Verzenio, Jaypirca |
| Eisai INC. | $378.08 | 2021-2025 | |
| Beigene USA, INC. | $362.50 | 2021-2024 | Brukinsa |
| Karyopharm Therapeutics INC. | $359.73 | 2021-2024 | Xpovio |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $337.26 | 2023-2025 | Tivdak, Epkinly |
| Pfizer INC. | $318.24 | 2021-2025 | |
| Stemline Therapeutics INC. | $316.01 | 2023-2025 | Orserdu |
| Sobi, INC | $313.66 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $313.41 | 2021-2025 | |
| Abbvie INC. | $308.82 | 2022-2025 | |
| Incyte Corporation | $304.45 | 2021-2025 | Monjuvi, Jakafi, Monjuvi |
| Tactile Systems Technology INC | $293.84 | 2024-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Fennec Pharmaceuticals, INC. | $287.55 | 2024-2025 | Pedmark, Fyarro |
| Amgen INC. | $287.28 | 2021-2025 | Imdelltra (Amg757), Nplate, Vectibix |
| Daiichi Sankyo INC. | $272.92 | 2022-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $241.20 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $221.16 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Exelixis INC. | $204.88 | 2021-2025 | Cabometyx |
| Adaptive Biotechnologies Corporation | $187.86 | 2024-2025 | Clonoseq |
| Servier Pharmaceuticals LLC | $181.21 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $163.82 | 2024-2025 | |
| Mirati Therapeutics, INC. | $162.62 | 2023 | Krazati |
| Ipsen Biopharmaceuticals, INC | $159.12 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $158.70 | 2025 | Monoferric |
| Puma Biotechnology, INC. | $154.74 | 2021 | |
| Agios Pharmaceuticals, INC. | $147.19 | 2023-2025 | Pyrukynd |
| Seagen INC. | $135.74 | 2021-2022 | |
| Genentech, INC. | $120.80 | 2025 | Columvi |
| Astellas Pharma Global Development | $118.63 | 2021 | |
| Jazz Pharmaceuticals INC. | $117.19 | 2022-2023 | |
| Cti Biopharma Corp. | $113.40 | 2022-2023 | Vonjo |
| Rigel Pharmaceuticals, INC. | $111.96 | 2021-2024 | Tavalisse, Rezlidhia |
| Epizyme, INC. | $111.44 | 2021 | |
| Beone Medicines USA, INC. | $109.49 | 2025 | Tevimbra, Brukinsa |
| Foundation Medicine, INC. | $102.48 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $76.91 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.21 | 2023-2025 | Gilotrif |
| Clovis Oncology, INC. | $67.44 | 2021 | |
| Taiho Oncology, INC. | $65.24 | 2021-2024 | |
| Emd Serono, INC. | $56.59 | 2022-2025 | Bavencio |
| Array Biopharma INC | $53.91 | 2025 | Braftovi, Mektovi, Tukysa |
| Blueprint Medicines Corporation | $43.71 | 2023-2024 | Ayvakit |
| Adc Therapeutics America, INC. | $42.28 | 2023-2024 | |
| Kyowa Kirin, INC. | $36.40 | 2023-2025 | Poteligeo |
| Caris Mpi, INC. | $30.31 | 2025 | Mi Cancer Seek |
| Immunocore Limited | $29.97 | 2025 | Kimmtrak |
| Springworks Therapeutics, INC. | $27.77 | 2025 | Ogsiveo |
| Immunogen, INC. | $27.40 | 2023 | Elahere |
| Pharmacyclics LLC, An Abbvie Company | $24.22 | 2023 | Imbruvica |
| Astellas Pharma US INC | $21.18 | 2023 | Padcev |
| G1 Therapeutics, INC. | $20.81 | 2022 | |
| Recordati_rare_diseases_inc. | $20.71 | 2025 | Sylvant |
| Geron Corporation | $19.53 | 2025 | Rytelo |
| Janssen Pharmaceuticals, INC | $18.40 | 2022 | |
| Tersera Therapeutics LLC | $18.35 | 2023 | Zoladex |
| Tempus Ai, INC | $18.02 | 2024 | |
| Cycle Pharmaceuticals INC | $15.67 | 2025 | Phyrago |
| Celgene Corporation | $14.95 | 2025 | Reblozyl |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Sperl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.